(Q33344528)

26 July 2017

1 reference

title

Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions (English)

1 reference

Ibrahim Celalettin Haznedaroglu

26 July 2017

author

object named as

Ibrahim C Haznedaroglu

1

0 references

author name string

Hakan Goker

2

1 reference

26 July 2017

Mehmet Turgut

3

1 reference

26 July 2017

Yahya Buyukasik

4

1 reference

26 July 2017

Mustafa Benekli

5

1 reference

26 July 2017

language of work or name

1 reference

1 July 2002

1 reference

Clinical and Applied Thrombosis-Hemostasis

26 July 2017

published in

1 reference

26 July 2017

volume

8

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

193-212

1 reference

Clinical issues and treatment advances in thrombocytopenia: introduction

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Pharmacologic treatment options in patients with thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Targeted approaches for the treatment of thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Regulation of megakaryocytopoiesis and platelet production: lessons from animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Thrombocytopenia in c-mpl-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Purification and characterization of thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Molecular cloning and chromosomal localization of the human thrombopoietin gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Thrombopoietin: a pan-hematopoietic cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Cloning and characterization of the human megakaryocyte growth and development factor (MGDF) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Transcriptional regulation in megakaryocytes: the thrombopoietin receptor gene as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

The human homolog of the myeloproliferative virus maps to chromosome band 1p34

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Thrombopoietin signal transduction requires functional JAK2, not TYK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Native thrombopoietin: structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Recombinant human thrombopoietin clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Promegapoietin-1a, an engineered chimeric IL-3 and Mpl-L receptor agonist, stimulates hematopoietic recovery in conventional and abbreviated schedules following radiation-induced myelosuppression in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Discovery of a novel thrombopoietin mimic agonist peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

A non-peptide compound which can mimic the effect of thrombopoietin via c-Mpl

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Effects of megakaryocyte growth and development factor (thrombopoietin) on liver endothelial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Plasma thrombopoietin in patients with cavernous transformation of the portal vein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

The role of the liver in the production of thrombopoietin compared with erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Regulation of platelet production: "thrombopoietin".

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Binding and regulation of thrombopoietin to human megakaryocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Thrombopoietin, interleukin-6, and P-selectin at diagnosis and during post-steroid recovery period of patients with autoimmune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Thrombocytopenia caused by the development of antibodies to thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

The use of PEG-rhuMGDF in platelet apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Thrombopoietin therapy increases platelet yields in healthy platelet donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG‐rHuMGDF

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Effective ex vivo generation of megakaryocytic cells from mobilized peripheral blood CD34(+) cells with stem cell factor and promegapoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Thrombopoietic factors potentially useful in the treatment of acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Response to hypoxia involves transforming growth factor-beta2 and Smad proteins in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Effect of thrombopoietin on acute myelogenous leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Thrombopoietin activates the growth of megakaryoblasts in patients with chronic myeloproliferative disorders and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Future directions with platelet growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

The pharmacokinetics and pharmacodynamics of GW395058, a peptide agonist of the thrombopoietin receptor, in the dog, a large-animal model of chemotherapy-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

Failing to live up to the fanfare? A personal perspective on obstacles to the clinical development of thrombopoietic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960200800301

10.1177/107602960200800301

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference